Free fatty acids block glucose-induced β-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18.

TitleFree fatty acids block glucose-induced β-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18.
Publication TypeJournal Article
Year of Publication2012
AuthorsPascoe J, Hollern D, Stamateris R, Abbasi M, Romano LC, Zou B, O'Donnell CP, Garcia-Ocaña A, Alonso LC
JournalDiabetes
Volume61
Issue3
Pagination632-41
Date Published2012 Mar
ISSN1939-327X
KeywordsAnimals, Cell Proliferation, Cyclin D2, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase Inhibitor p18, Emulsions, Fatty Acids, Nonesterified, Glucose, Insulin-Secreting Cells, Male, Mice, Mice, Inbred C57BL, Phospholipids, Rats, Safflower Oil, Soybean Oil
Abstract

Pancreatic β-cell proliferation is infrequent in adult humans and is not increased in type 2 diabetes despite obesity and insulin resistance, suggesting the existence of inhibitory factors. Free fatty acids (FFAs) may influence proliferation. In order to test whether FFAs restrict β-cell proliferation in vivo, mice were intravenously infused with saline, Liposyn II, glucose, or both, continuously for 4 days. Lipid infusion did not alter basal β-cell proliferation, but blocked glucose-stimulated proliferation, without inducing excess β-cell death. In vitro exposure to FFAs inhibited proliferation in both primary mouse β-cells and in rat insulinoma (INS-1) cells, indicating a direct effect on β-cells. Two of the fatty acids present in Liposyn II, linoleic acid and palmitic acid, both reduced proliferation. FFAs did not interfere with cyclin D2 induction or nuclear localization by glucose, but increased expression of inhibitor of cyclin dependent kinase 4 (INK4) family cell cycle inhibitors p16 and p18. Knockdown of either p16 or p18 rescued the antiproliferative effect of FFAs. These data provide evidence for a novel antiproliferative form of β-cell glucolipotoxicity: FFAs restrain glucose-stimulated β-cell proliferation in vivo and in vitro through cell cycle inhibitors p16 and p18. If FFAs reduce proliferation induced by obesity and insulin resistance, targeting this pathway may lead to new treatment approaches to prevent diabetes.

DOI10.2337/db11-0991
Alternate JournalDiabetes
PubMed ID22338094
PubMed Central IDPMC3282818
Grant ListDK077096 / DK / NIDDK NIH HHS / United States
DK067351 / DK / NIDDK NIH HHS / United States
P30 DK046204 / DK / NIDDK NIH HHS / United States
R01 DK095140 / DK / NIDDK NIH HHS / United States
R01 HL063767 / HL / NHLBI NIH HHS / United States
HL063767 / HL / NHLBI NIH HHS / United States
K08 DK076562 / DK / NIDDK NIH HHS / United States
R01 DK067351 / DK / NIDDK NIH HHS / United States
DK076562 / DK / NIDDK NIH HHS / United States
R01 DK077096 / DK / NIDDK NIH HHS / United States
DK046204 / DK / NIDDK NIH HHS / United States